Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 103

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 4
Chunk 103
---
 website, in addition to following our press releases, SEC filings and public conference calls and webcasts.
The contents of our website are not, however, a part of this Annual Report on Form 20-F.

As a foreign private issuer, we are exempt from
certain rules and regulations under the Exchange Act that are applicable to other public companies that are not foreign private issuers.
For example, although we intend to report our financial results on a quarterly basis, we will not be required to issue quarterly reports,
proxy statements that comply with the requirements applicable to U. S. domestic reporting companies, or individual executive compensation
information that is as detailed as that required of U. S. domestic reporting companies. We will also have four months after the end of
each fiscal year to file our annual report with the SEC and will not be required to file current reports as frequently or promptly as
U. S. domestic reporting companies. Our senior management, directors, and principal shareholders will be exempt from the requirements to
report transactions in our equity securities and from the short-swing profit liability provisions contained in Section 16 of the
Exchange Act. As a foreign private issuer, we will also not be subject to the requirements of Regulation FD (Fair Disclosure) promulgated
under the Exchange Act.

B. Business Overview

Overview

We are a clinical pharmaceutical company currently
engaged in phase I/IIa clinical trials of novel psychedelic medicines to solve widespread, yet under-served, health problems. Our goal
is to develop and provide new type of treatments for mental health disorders, including AUD, binge drinking and eating disorders, where
there is significant unmet need and lack of innovation. We see psychedelic therapies, which previously may have been overlooked or underused,
as the future of treatment for a variety of indications. We believe that our solution for AUD can help solve one of the world’s
biggest health problems, which costs the United States alone roughly $250 billion each year.

Our flagship treatment and focus for the short
term is on AUD, which is incredibly common. It varies from mild to excessive and describes a person’s inability to restrict their
alcohol consumption, despite negative social, occupational, or health consequences. Alcohol consumption contributes to 3 million deaths
each year globally and is the third most common preventable cause of death in the United States. In January 2025, the U. S. Surgeon General
released a new Surgeon General’s Advisory on Alcohol and Cancer Risk, outlining the direct link between